879088-41-2 Vismodegib Intermediate
Product name:4-chloro-3-(pyridin-2-yl)anilineCAS:879088-41-2. MF:C11H9ClN2. MW:204.66. EINECS:. MDL No.:MFCD12024455
Add to Inquiry
CAS 875781-43-4 | 5-Bromo-4,7-diazaindole
Name: 5-Bromo-4,7-diazaindoleCAS number: 875781-43-4Molecular formula: C6H4BrN3Molecular weight: 198.02EINECS number: 1308068-626-2MDL No.：MFCD09834822
Add to Inquiry
CAS 909542-99-0 | Benfooxythiamine
Name: BenfoxythiamineCAS number: 909542-99-0Molecular formula: C19H22N3O7PSMolecular weight: 467.43EINECS number:MDL No.：
Add to Inquiry
82419-35-0 Oxygen-fluorine Acid
CAS:82419-35-0MF:C13H9F2NO4MW:281.21EINECS:700-160-8MDL No.:MFCD00226106
Add to Inquiry
60066-88-8 β-Sinensal
Product name: β-SinensalCAS number: 60066-88-8Molecular formula: C15H22OMolecular weight: 218.33EINECS number: 262-043-3MDL No.：MFCD03788249
Add to Inquiry
204521-63-1 Pal-Glu(OSU)-OtBu
Product name: N ε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-ert body EsterCAS number: 204521-63-1Molecular formula: C29H50N2O7Molecular weight: 538.72EINECS number:MDL No.：MFCD22989465
Add to Inquiry
55117-15-2 2-Chloro-6-fluorobenzyl Chloride
Product name: 2-Chloro-6-fluorobenzyl chlorideCAS number: 55117-15-2Molecular formula: C7H5Cl2FMolecular weight: 179.02EINECS number: 259-487-5MDL No.：MFCD00000896
Add to Inquiry
1211443-61-6
Product name: 2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamideCAS:1211443-61-6. MF:C14H17ClN4O. MW:292.76. EINECS:808-234-2. MDL No.:MFCD20527881
Add to Inquiry
312753-53-0
Product Name:5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochlorideCAS:312753-53-0. MF:C13H20ClN. MW:225.76. EINECS:691-331-5. MDL No.:MFCD13185940
Add to Inquiry
530084-79-8
CAS:530084-79-8
Add to Inquiry
54527-65-0 2-(benzylmethylamino)ethyl Acetoacetate
CAS:54527-65-0. MF:C14H19NO3. MW:249.31. EINECS:259-197-9. MDL No.:MFCD00071539
Add to Inquiry
3610-36-4
CAS:3610-36-4. MF:C11H14N2O. MW:190.24. EINECS:222-778-2. MDL No.:MFCD00005663
Add to Inquiry
China Vismodegib intermediate Manufacturers Factory Suppliers
We are a professional integrated system intermediate, complementary intermediate, Pazopanib intermediate manufacturer integrating development, design, production and sales, and our products reflect the characteristics of the times.We believe we will be able to bring you the most satisfactory Vismodegib intermediate and services based on the principle of excellence, honesty and customer first. We are committed to ensuring the satisfaction of our customers, no matter what. "Professional quality, low price, good quality and considerate service" is our consistent purpose. We sincerely look forward to working with you to create a better future. We have a perfect quality inspection system to ensure the qualification rate of our products, and some of them have successfully entered the international market. We regulate people with strict rules and regulations, demand people with rigorous work style, guide people with noble moral sentiment and unite people with harmonious humanistic atmosphere. Since its establishment, we have served every customer with the principle of "customer first, honesty first", so we have gained the full trust of many customers.
Juan Harper
Michael Phillips
Wallace Adams
Sue Taggart
Nicole Stroman
Arlene Winter
WEBSep 24, 2018 · In this phase Ib study, ten patients with intermediate- or high-risk primary or secondary MF received open-label vismodegib (150 mg/day orally) and ruxolitinib (15 or 20 mg orally...
WEBSep 24, 2018 · Methods: In this phase Ib study, ten patients with intermediate- or high-risk primary or secondary MF received open-label vismodegib (150 mg/day orally) and ruxolitinib (15 or 20 mg...
WEBDec 7, 2017 · Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis | Blood |...
WEBPublished: 20 December 2019. Clinical Study. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic......
WEBJun 7, 2012 · A phase 1 study of vismodegib involving 33 patients with advanced basal-cell carcinoma showed a 58% confirmed response rate and a median duration of response of 12.8 months. 4,5 This...
WEBNov 30, 2018 · Methods: In this phase Ib study, ten patients with intermediate- or high-risk primary or secondary MF received open-label vismodegib (150 mg/day orally) and ruxolitinib (15 or 20 mg...
